Kevin U. Stephens, Sr, JD, MD

Kevin U. Stephens, Sr., JD, MD, leads a discussion exploring the key drivers of cost for patients with wet age-related macular degeneration (AMD).

Experts highlight early detection and the goals of therapy when managing patients with glaucoma.

A brief overview of vision preservation in glaucoma and the importance of preventing peripheral vision loss and patient falls.

Nicholas G. Anderson, MD, and Philip Niles, MD, MBA, provide an overview of diabetic macular edema (DME) and the impact of vision impairment on a patient’s quality of life.

Philip Niles, MD, MBA, and Nicholas G. Anderson, MD, define wet age-related macular degeneration (AMD) and review clinical manifestations of the disease.

Panelists discuss the worldwide gaps in diagnosis of glaucoma and how this negatively affects patient outcomes.

Shared insight on factors that put patients at risk for glaucoma and how screening can improve early diagnosis and care.

Closing out their discussion on recurrent clostridium difficile infection management, experts share closing thoughts and hopes for the future.

Panelists review unmet needs in clostridium difficile infection management and consider how medical policies are evolving to address them.

Shared insight on the process to gain access to fecal microbiota transplant for patients with clostridium difficile infection.

A focused discussion on the barriers to fecal microbiota transplant for patients with clostridium difficile infection.

Experts focus on the current state of fecal microbiota transplant as a treatment option for clostridium difficile infection.

Panelists take a step back to consider the broader challenges in managing patients with clostridium difficile infection.

Payer participants consider how they proactively risk stratify patients for clostridium difficile infection recurrence.

An overview on how the cost of therapy for recurrent clostridium difficile infection may impact treatment planning.

Focused discussion on the use of fidaxomicin for clostridium difficile infection, and possible barriers to the selection of this agent.

Payer participants break down how coverage criteria are determined for treatments for clostridium difficile infection.

Shared insight on the differences between ACG and IDSA/SHEA treatment guidelines for patients with clostridium difficile infection.

A panel of experts review treatment goals and assessing response in patients with recurrent clostridium difficile infection.

A broad view on the impact of recurrent clostridium difficile infection on patients and the healthcare system at large.

Experts focus on recurrent clostridium difficile infection to define risk factors and discuss impact on patient outcomes.

Opening their discussion, panelists elucidate patient factors that may impact risk of developing clostridium difficile infection.

Take-aways from a discussion on the management of cold agglutinin disease, with expert insight on navigating the healthcare system to optimize patient care.

Considerations regarding where newer, novel complement therapies will likely fit into the treatment landscape for patients with cold agglutinin disease.

Payers debate criteria for coverage of novel targeted therapies under investigation as use as novel complement therapy for cold agglutinin disease.

Payers react to gaps that impact coverage decisions for therapies available off-label for cold agglutinin disease.

Criteria that support coverage decisions for anti–B-cell therapies for cold agglutinin disease, which are not currently FDA approved.

Payer considerations regarding the measurement of treatment outcomes for patients with cold agglutinin disease, and resources available to help support patients through their care continuum.

Payers comment on main drivers of health care utilization among patients with cold agglutinin disease.

Experts in SMA provide closing thoughts on unmet needs in SMA including the importance of research into treatment combinations and sequencing as well as multidisciplinary care and healthcare equity.